Therapy Areas: Autoimmune
Sanofi's rilzabrutinib receives US orphan drug designation for two rare diseases
3 April 2025 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Thursday that the US Food and Drug Administration has granted orphan drug designation to rilzabrutin...
Organon acquires US rights to TOFIDENCE from Biogen
1 April 2025 - Healthcare company Organon (NYSE:OGN) announced on Tuesday that it has acquired the US regulatory and commercial rights to TOFIDENCE, a biosimilar to ACTEMRA, from biotechnology company...
Bio-Thera Solutions signs commercialisation and licence agreements with Dr. Reddy's Laboratories
28 March 2025 - Commercial-stage biopharmaceutical company Bio-Thera Solutions (SH:688177:SH) announced on Thursday that it has signed commercialisation and licence agreements with Dr. Reddy's La...
Hemogenyx's CAR-T therapy passes initial safety tests in Phase I trial
24 March 2025 - Biopharmaceutical group Hemogenyx Pharmaceuticals plc (LSE: HEMO) announced on Monday that it has successfully treated the first patient in its Phase I clinical trial of HG-CT-1, a pro...
Syneron Bio to collaborate with AstraZeneca
24 March 2025 - Syneron Bio, a China-based oral macrocyclic peptide drug biotech company, announced on Friday that it is collaborating with AstraZeneca, a UK-based global biopharmaceutical company, to...
Everest Medicines' EVM14 IND application receives US FDA approval
24 March 2025 - Everest Medicines (HKEX 1952.HK), a China-based biopharmaceutical company, announced on Sunday that it has received approval from the US Food and Drug Administration (FDA) for its Inve...